BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKesson
Johnson and Johnson
US Department of Justice
Chubb
Accenture
Merck
Argus Health
Healthtrust
Fuji

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,983,594

« Back to Dashboard

Which drugs does patent 8,983,594 protect, and when does it expire?

Patent 8,983,594 protects ZECUITY and is included in one NDA.

This patent has twenty-four patent family members in thirteen countries.
Summary for Patent: 8,983,594
Title:Electronic control of drug delivery system
Abstract: In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.
Inventor(s): Saar; David (Titusville, NJ), Baudis; Bogdan Mariusz (Stoneham, MA), Gupta; Rainuka (Cambridge, MA), Kamat; Vaishali Vilas (Arlington, MA), Reich; Matthew Kent (Medford, MA), Srinivasan; Rajagopalan (Cambridge, MA)
Assignee: NuPathe, Inc. (Malvern, PA)
Application Number:12/648,726
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 8,983,594

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded Pharm ZECUITY sumatriptan succinate SYSTEM;IONTOPHORESIS 202278-001 Jan 17, 2013 DISCN Yes No ➤ Subscribe ➤ Subscribe Y METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,983,594

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015242986 ➤ Subscribe
Brazil PI0923808 ➤ Subscribe
Canada 2748569 ➤ Subscribe
Canada 2944660 ➤ Subscribe
China 102333566 ➤ Subscribe
China 104043194 ➤ Subscribe
Eurasian Patent Organization 201100891 ➤ Subscribe
European Patent Office 2393549 ➤ Subscribe
European Patent Office 2810688 ➤ Subscribe
European Patent Office 3120895 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Novartis
Colorcon
Accenture
Chinese Patent Office
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot